Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
1.25 EUR
343.00 M EUR
5.25 B EUR
116.68 M
About UCB
Sector
CEO
Jean-Christophe Tellier
Headquarters
Brussels
Website
Founded
1925
ISIN
BE0003739530
FIGI
BBG00K0C9008
UCB SA engages in the research and development of biopharmaceuticals products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.
UCB.BR short term bullish potential to challenge ATHConclusion:
A substantial break above 100, preferably above 107 signals a short term bullish potential, challenging ATH and beyond.
A drop below 75 on the other hand renders long term bearish or at least choppy consolidation.
For short term play targeting 108 minimally, with tight stop just under 96
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of UCB is 172.20 EUR — it has increased by 1.74% in the past 24 hours. Watch UCB stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on VIE exchange UCB stocks are traded under the ticker UCB.
UCB stock has fallen by −5.80% compared to the previous week, the month change is a −0.35% fall, over the last year UCB has showed a 151.75% increase.
We've gathered analysts' opinions on UCB future price: according to them, UCB price has a max estimate of 250.00 EUR and a min estimate of 145.00 EUR. Watch UCB chart and read a more detailed UCB stock forecast: see what analysts think of UCB and suggest that you do with its stocks.
UCB stock is 1.74% volatile and has beta coefficient of 1.03. Track UCB stock price on the chart and check out the list of the most volatile stocks — is UCB there?
Today UCB has the market capitalization of 32.23 B, it has decreased by −4.55% over the last week.
Yes, you can track UCB financials in yearly and quarterly reports right on TradingView.
UCB is going to release the next earnings report on Feb 27, 2025. Keep track of upcoming events with our Earnings Calendar.
UCB earnings for the last half-year are 2.09 EUR per share, whereas the estimation was 1.76 EUR, resulting in a 18.58% surprise. The estimated earnings for the next half-year are 2.58 EUR per share. See more details about UCB earnings.
UCB revenue for the last half-year amounts to 2.79 B EUR, despite the estimated figure of 2.68 B EUR. In the next half-year revenue is expected to reach 2.98 B EUR.
UCB net income for the last half-year is 208.00 M EUR, while the previous report showed 32.00 M EUR of net income which accounts for 550.00% change. Track more UCB financial stats to get the full picture.
Yes, UCB dividends are paid annually. The last dividend per share was 0.95 EUR. As of today, Dividend Yield (TTM)% is 0.56%. Tracking UCB dividends might help you take more informed decisions.
UCB dividend yield was 1.21% in 2023, and payout ratio reached 52.65%. The year before the numbers were 1.27% and 42.23% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Nov 21, 2024, the company has 9.08 K employees. See our rating of the largest employees — is UCB on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. UCB EBITDA is 1.20 B EUR, and current EBITDA margin is 18.47%. See more stats in UCB financial statements.
Like other stocks, UCB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade UCB stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So UCB technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating UCB stock shows the buy signal. See more of UCB technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.